Publication | Closed Access

Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF)

Neuro-oncologySurgical OncologyFirst-line MolecularMedicineAdvanced ChordomaPathologySpinal OncologySpinal TumorMolecular OncologyOncologyRadiation OncologyFrench Sarcoma GroupCancer Research